Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 2/20 | 0.83 |
| ▸ | CCR1 | P32246 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HRH1 | P35367 | 4/20 | 0.50 |
| ▸ | CCR3 | P51677 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3805993 | 0.94 | ABCB11 (0.79) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL14093760 | 0.94 | ABCB11 (0.79) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL3813533 | 0.93 | ABCB11 (0.81) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL3813060 | 0.93 | ABCB11 (0.81) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL3813054 | 0.93 | ABCB11 (0.81) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL3810709 | 0.93 | ABCB11 (0.83) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL3813287 | 0.92 | ABCB11 (0.77) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL3813518 | 0.91 | ABCB11 (1.00) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL3676228 | 0.90 | ABCB11 (0.75) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL3676233 | 0.90 | ABCB11 (0.75) | ABCB11CCR1LMNAHRH1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136843-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | claimed |
| EP-2125728-A1 | NOVEL COMBINATION OF COMPOUNDS TO BE USED IN THE TREATMENT OF AIRWAY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | AstraZeneca AB (SE) | 2009-12-02 | — | — | EP | claimed |
| WO-2008104776-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | claimed |
| WO-2008103125-A1 | NOVEL COMBINATION OF COMPOUNDS TO BE USED IN THE TREATMENT OF AIRWAY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | WO | claimed |
| EP-2364704-A1 | Combination of beta-adrenoceptor agonist and corticosteroid | AstraZeneca AB (SE) | 2011-09-14 | — | — | EP | disclosed |
| WO-2011073662-A1 | COMBINATION OF A BENZOXAZINONE AND A FURTHER AGENT FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | WO | disclosed |
| US-20110136843-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| EP-2303266-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2, 3- DIHYDRO-1, 3-BENZOTHIAZOL-7-YL COMPOUND FOR MODULATION OF BETA2-ADRENORECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| US-20100144606-A1 | COMBINATION 408 | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100029732-A1 | Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| WO-2010004319-A1 | COMBINATION COMPRISING 6-FLU0R0-N- ((1S, 4S) - 4- (6-FLUORO-2, 4-DI0X0-1- (4'- (PIPERAZIN-1- YLMETHYL) BIPHENYL- 3-YL) -1, 2-DIHYDROPYRIDO [2, 3-D] PYRIMIDIN-3 (4H) - YL) CYCLOHEXYL) IMIDAZO [1,2-A] PYRIDINE -2- CARBOXAMIDE OR A SALT | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009154562-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2, 3- DIHYDRO-1, 3-BENZOTHIAZOL-7-YL COMPOUND FOR MODULATION OF BETA2-ADRENORECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| EP-2125728-A1 | NOVEL COMBINATION OF COMPOUNDS TO BE USED IN THE TREATMENT OF AIRWAY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | AstraZeneca AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009142588-A1 | COMBINATION OF (A) A CHEMOKINE RECEPTOR 1 (CCR1) ANTAGONIST AND (B) GLUCOCORTICOID RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | WO | disclosed |
| EP-2117542-A1 | COMBINATIONS OF BETA- 2 -ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | AstraZeneca AB (SE) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009037503-A2 | NEW COMBINATION - 012 FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2009-03-26 | — | — | WO | disclosed |
| US-20080242649-A1 | New Combination 665 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| WO-2008103125-A1 | NOVEL COMBINATION OF COMPOUNDS TO BE USED IN THE TREATMENT OF AIRWAY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008096136-A1 | COMBINATIONS WITH A MUSCARINIC RECEPTOR ANTAGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096111-A1 | COMBINATIONS OF BETA- 2 -ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144606-A1 | COMBINATION 408 | NR3C2, PTGER2, LTB4R2 | ABCB11 1536/4885CCR1 24/4885LMNA 2468/4885 |
| US-20080242649-A1 | New Combination 665 | NR3C2, PTGER2, GRK5 | ABCB11 2075/4885CCR1 29/4885LMNA 3129/4885 |
| US-20110136843-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | CCR1, CCR5, CCR3 | ABCB11 1009/4885CCR1 1/4885LMNA 3862/4885 |
| US-20100029732-A1 | Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone | NR3C2, NR3C1, ARRB1 | ABCB11 1971/4885CCR1 103/4885LMNA 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.